Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL11188973 | 1.00 | TRHR (0.46) | TRHR | |
| SCHEMBL7307730 | 0.92 | TRHR (0.53) | TRHR | |
| SCHEMBL4957292 | 0.92 | TRHR (0.53) | TRHR | |
| SCHEMBL11189804 | 0.92 | TRHR (0.53) | TRHR | |
| Citric Acid SCHEMBL30391067 | 0.86 | TRHR (0.61) | TRHR | |
| SCHEMBL8256990 | 0.80 | TRHR (0.40) | TRHR | |
| SCHEMBL14028670 | 0.80 | TRHR (0.41) | TRHR | |
| SCHEMBL7327392 | 0.78 | TRHR (0.51) | TRHR | |
| SCHEMBL7334673 | 0.77 | TRHR (0.51) | TRHR | |
| Azetirelin SCHEMBL10703548 | 0.77 | TRHR (0.62) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8568997-B2 | Detection system and uses therefor | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2013-10-29 | — | — | US | disclosed |
| EP-2605015-A1 | Kits for determining the interaction of a test compound with two associated receptors | Dimerix Bioscience Pty.Ltd. (AU) | 2013-06-19 | — | — | EP | disclosed |
| EP-2080012-B1 | Methods for assaying test compounds on associated receptors | DIMERIX BIOSCIENCE PTY LTD (AU) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065253-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2013-03-14 | — | — | US | disclosed |
| US-8283127-B2 | Detection system and uses therefor | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2012-10-09 | — | — | US | disclosed |
| US-20100234417-A1 | THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2010-09-16 | — | — | US | disclosed |
| US-20100021457-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2010-01-28 | — | — | US | disclosed |
| EP-2080012-A1 | DETECTION SYSTEM AND USES THEREFOR | Dimerix Bioscience Pty.Ltd. (AU) | 2009-07-22 | — | — | EP | disclosed |
| EP-2078037-A1 | THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS | Dimerix Bioscience Pty.Ltd. (AU) | 2009-07-15 | — | — | EP | disclosed |
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | ROGER WILLIAMS HOSPITAL (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008055314-A1 | THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS | DIMERIX BIOSCIENCE PTY LTD (AU) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055313-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD (AU) | 2008-05-15 | — | — | WO | disclosed |
| EP-1901763-A2 | THYROTROPIN-RELEASING HORMONE ANALOGS AND METHOD OF USE | Roger Williams Hospital (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006096829-A2 | THYROTROPIN-RELEASING HORMONE ANALOGS AND METHOD OF USE | ROGER WILLIAMS HOSPITAL (US) | 2006-09-14 | — | — | WO | disclosed |
| US-5686420-A | Thyrotropin-releasing hormone analogs and method of use | GEORGETOWN UNIVERSITY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0422140-A1 | THYROLEBERIN AS IMMUNOMODULATOR AND LIPID REGULATOR | PIERPAOLI, Walter (CH) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990008583-A2 | THYROLEBERIN AS IMMUNOMODULATOR AND LIPID REGULATOR | PIERPAOLI WALTER (CH) | 1990-08-09 | — | — | WO | disclosed |
| EP-0119737-A2 | Pharmaceutical composition and its production | Takeda Chemical Industries, Ltd. (JP) | 1984-09-26 | — | — | EP | disclosed |
| US-4421745-A | PEPTIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | TRHR, IAPP, TRHDE | TRHR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.